One theory on Ariflo difficulties
Executive Summary
Variable results seen in clinical trials of the PDE4 inhibitor Ariflo for chronic obstructive pulmonary disease may be due to patient selection, GSK VP-New Product Development James Palmer speculates during Goldman Sachs conference. "I think you are seeing some probably asthmatic patients or other types of patients getting into these studies who have some reversibility, which probably accounts for some of the variable results that you are seeing," Palmer said. Development of Ariflo was delayed after a pivotal European trial failed to reach statistical significance (1"The Pink Sheet" Nov. 6, 2000, p. 4). A follow-up study is recruiting patients and one-year data is expected to be filed in the second half of 2002, Palmer said. GSK's Advair (salmeterol/fluticasone) was filed for COPD in May
You may also be interested in...
SB Paxil Exclusivity Defense: Synthon Files NDA For Paroxetine Mesylate
SmithKline Beecham could face competition to its antidepressant Paxil in the U.S. from an NDAed version of a different salt of paroxetine filed by Synthon.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials